Goldman Sachs resumes Alkermes stock coverage with neutral rating
Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.
How this was made
The 30-second read
Why it matters
Analyst coverage resumption and positive Phase 1b data provide fresh upside catalysts, but valuation remains stretched.
Market read
New analyst rating and trial data could drive short‑term price movement; sector peers may see indirect benefit.
What to watch
Potential regulatory hurdles and the need for later‑stage data could temper upside.
Background
Alkermes (NASDAQ:ALKS) is a biopharma with neuropsychiatric products; coverage changes and early trial data are new developments.
Ticker impact
Goldman Sachs resumed coverage on Alkermes with a Neutral rating and a $50 price target, and disclosed Phase 1b trial results for ALKS 7290 showing proof‑of‑concept in ADHD.
Potential upside of ~15‑20% if market digests the trial data and rating change.
Coverage resumption and higher price target provide a fresh catalyst; trial data adds clinical upside.
Market effects
Positive signal for neuropsychiatric biotech sector as trial data may boost peer valuations.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech-focused funds.
Counterpoint
The high P/E and early‑stage pipeline may still pose valuation risk despite the trial news.
Key entities
- AnalystGoldman Sachs
Resumed coverage with Neutral rating and $50 target.
- CompanyAlkermes plc
Biopharma reporting Phase 1b trial results for ALKS 7290.
